Cargando…

Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review

Objective: This study aims to synthesize evidence on the cost-effectiveness of empagliflozin for heart failure (HF). Methods: MEDLINE, Embase, the Cochrane Library, EconLit, CNKI, Wanfang Data and Chongqing VIP were searched to identify original articles on cost-effectiveness of empagliflozin for HF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jinyu, Liu, Dong, Gong, Xuepeng, Wei, Anhua, You, Ruxu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348886/ https://www.ncbi.nlm.nih.gov/pubmed/37456744 http://dx.doi.org/10.3389/fphar.2023.1186579

Ejemplares similares

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
por: Tang, Yi, et al.
Publicado: (2022)

Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China
por: Liu, Jinyu, et al.
Publicado: (2021)

Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review
por: Liu, Jinyu, et al.
Publicado: (2022)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2020)

Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia
por: Ong, Siew Chin, et al.
Publicado: (2023)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Cost effectiveness analyses of pharmacological treatments in heart failure
por: Lim, Audrey Huili, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
por: Sang, Haiqiang, et al.
Publicado: (2022)

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
por: You, Ruxu, et al.
Publicado: (2018)

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence
por: You, Ruxu, et al.
Publicado: (2020)

Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England
por: Kolovos, Spyros, et al.
Publicado: (2023)

Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%
por: Kolovos, Spyros, et al.
Publicado: (2023)

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review
por: Wu, Meiyu, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective
por: Lin, Xiaohui, et al.
Publicado: (2022)

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
por: Hu, Tianyang, et al.
Publicado: (2023)

Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess
por: Li, Mingming, et al.
Publicado: (2023)

A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
por: Tafazzoli, Ali, et al.
Publicado: (2022)

Efficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis
por: Wei, Penglu, et al.
Publicado: (2021)

Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?
por: Mann, Douglas L., et al.
Publicado: (2017)

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Xinbao Pill in Chronic Heart Failure
por: Wang, Yuanping, et al.
Publicado: (2022)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2023)

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
por: Hallinen, Taru, et al.
Publicado: (2023)

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
por: Wan, Yuansheng, et al.
Publicado: (2023)

Empagliflozin in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Pan, Deng, et al.
Publicado: (2021)

Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
por: Ma, Yuting, et al.
Publicado: (2021)

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
por: Reifsnider, Odette S., et al.
Publicado: (2020)

Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
por: Jiang, Yaohui, et al.
Publicado: (2021)

Effects of Empagliflozin on Diuretics Reduction in Outpatient Heart Failure Patients
por: Kim, Soo-Jin, et al.
Publicado: (2022)

Efficacy and safety of Shenfu injection for the treatment of post-acute myocardial infarction heart failure: A systematic review and meta-analysis
por: Wu, Yanhua, et al.
Publicado: (2022)

A Systematic Review Exploring the Cardiovascular and Renal Effects of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction
por: Athiyaman, Sreekartthik, et al.
Publicado: (2022)

Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats
por: Ashraf, Ghulam Md, et al.
Publicado: (2021)

Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro
por: Li, Ting, et al.
Publicado: (2021)

Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis
por: Qin, Jianbin, et al.
Publicado: (2022)

Immunomodulatory Treatment Strategies Targeting B Cells for Heart Failure
por: Zhang, Xinxin, et al.
Publicado: (2022)

The synergistic compatibility mechanisms of fuzi against chronic heart failure in animals: A systematic review and meta-analysis
por: Liu, Xingyu, et al.
Publicado: (2022)

Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Real-world study of the leakage of two types of infusion bags in multicenter pharmacy intravenous admixture service (PIVAS)
por: Yin, Yanchao, et al.
Publicado: (2023)

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
por: Pietschner, R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nnkqe4jcire9v4v83tons39nmh